Sponsor
Aadi Bioscience, Inc.
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Aadi Bioscience, Inc. appears in 6 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
6 shownTrial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsNCT05997056 · lead sponsor · 2023-10-20
COMPLETEDPhase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)NCT05103358 · lead sponsor · 2022-03-10
COMPLETEDPhase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial HypertensionNCT02587325 · lead sponsor · 2017-04-01
COMPLETEDAdagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)NCT05840510 · collaborator · 2023-08-07
TERMINATEDA Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic SystemNCT03670030 · collaborator · 2018-11-05
TERMINATEDNivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersNCT03190174 · collaborator · 2017-08-24
COMPLETEDSponsor roles
collaborator3
lead sponsor3
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.